Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma
出版年份 2023 全文链接
标题
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma
作者
关键词
-
出版物
Current Oncology Reports
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-20
DOI
10.1007/s11912-023-01466-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
- (2023) Fabio Efficace et al. HemaSphere
- Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2023) Dai Chihara et al. BLOOD
- Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
- (2023) Jason R. Westin et al. CLINICAL CANCER RESEARCH
- CAR T‐cell therapy in large B cell lymphoma
- (2023) Alexander P. Boardman et al. HEMATOLOGICAL ONCOLOGY
- Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma
- (2023) Laura K. Hilton et al. JOURNAL OF CLINICAL ONCOLOGY
- ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
- (2023) Jason Westin et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
- (2023) Jason R. Westin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development
- (2023) Michael J. Dickinson et al. Cancer Discovery
- The race is on: bispecifics vs CAR T-cells in B-cell lymphoma
- (2023) Ashwath Gurumurthi et al. Blood Advances
- Cellular therapy in lymphoma
- (2023) Anna Sureda et al. HEMATOLOGICAL ONCOLOGY
- High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
- (2023) Edward R. Scheffer Cliff et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
- (2022) Jason Westin et al. BLOOD
- Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma
- (2022) Max J. Gordon et al. LEUKEMIA & LYMPHOMA
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
- (2022) Sattva S. Neelapu et al. NATURE MEDICINE
- Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
- (2022) Mahmoud Elsawy et al. BLOOD
- Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma
- (2022) Swetha Kambhampati et al. BLOOD
- Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
- (2022) Mi Kwon et al. HAEMATOLOGICA
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
- (2022) Manali Kamdar et al. LANCET
- Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
- (2022) Alison Sehgal et al. LANCET ONCOLOGY
- A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
- (2022) Emmanuel Bachy et al. NATURE MEDICINE
- Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
- (2022) Jeremy S. Abramson et al. Blood Advances
- Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study
- (2022) Jeremy S Abramson et al. BLOOD
- Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma
- (2022) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequencing therapy in relapsed DLBCL
- (2022) Christopher R. Flowers et al. Hematology-American Society of Hematology Education Program
- Diffuse Large B-Cell Lymphoma
- (2021) Laurie H. Sehn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
- (2021) Michael R. Bishop et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
- (2020) Sattva S. Neelapu et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
- (2019) Nancy L. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
- (2019) Yucai Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started